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BACKGROUND. Gastrointestinal tumors often contain high amounts of the detoxifi­
cation enzyme glutathione S-transferase Pl-1 (GSTP1-1). Elevated levels of GSTP1- 
1 were found in serum and plasma from most patients with gastrointestinal tumors. 
The authors evaluated the role of GSTP1-1 as a plasma tumor marker in patients 
with gastrointestinal tumors.
METHODS. A sensitive and specific sandwich enzyme-linked immunoadsorbent 
assay for quantification of GSTP1-1 in human plasma was developed.
RESULTS. GSTP1-1 levels in serum samples from 10 healthy controls were signifi­
cantly (JP < 0.0001) higher than in corresponding ethylenediaminetetraacetic acid 
(EDTA) plasma and varied with the type of blood collection tube used. Refrigeration 
or delayed centrifugation of blood collected in plain EDTA tubes resulted in spuri­
ously high plasma GSTP1-1 levels. Therefore, all plasma samples were collected 
in silicone-coated EDTA tubes. The distribution of plasma GSTP1-1 levels in 230 
blood donors was nearly normalized by logarithmic transformation and an upper 
normal reference level of 21,8 fxg/L was calculated. Males had significantly higher 
(P <  0.0001) plasma GSTP1-1 levels than females and a significant increase (JP <
0.004) in plasma GSTP1-1 with age was noted. In only 20 of 55 patients (36%) with 
gastrointestinal tumors was the plasma GSTP1-1 level above the upper normal 
reference limit. No significant decrease in plasma GSTP1-1 was noted in matched 
pairs of plasma samples collected from 17 patients before and at least 2 weeks 
after resection of the tumor.
CONCLUSIONS. The GSTP1-1 level in serum and plasma depends on the materials 
and methods used to collect the samples. Only 36% of the patients with gastrointes­
tinal tumors had elevated plasma GSTP1-1 levels that did not decrease after resec­
tion of the tumor. These findings argue against the use of GSTP1-1 as a serum or 
plasma marker for gastrointestinal tumors. Cancer 1997;80:873-80,
© 1997 American Cancer Society.
KEYWORDS: glutathione S-transferase PI-1, tumor marker, enzyme-linked immu­
noadsorbent assay, gastrointestinal carcinoma.
Glu tath ione S-transferases (GST) (Enzyme Commission of the In ternational U nion of Biochemistry 2.5.1.18) are enzymes that 
catalyze the addition of glutathione to electrophilic centers of a 
wide variety of compounds. This reaction is the first step in the 
form ation of m ercapturic acids, a pathway mostly resulting in the 
elim ination of potentially toxic compounds. GSTs also serve as 
transport proteins for a broad range of lipophilic com pounds, 
such as bilirubin, bile acids, steroid hormones, and various xeno- 
b io tics .1,2 The family of enzymes is divided into four classes: alpha,
© 1997 American Cancer Society
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mu,pi, and theta based on structural, physicochem ­
ical, enzymatic, and im m unologic p roperties .1“4
Malignancies from the colon, stomach, urinary 
bladder, uterine cervix, and lung often contain in ­
creased amounts of GSTP1-1 when compared with the 
adjacent normal tissue.5 In 1989 three studies were 
published, all indicating that a considerable number 
of patients with gastrointestinal malignancies had ele­
vated serum GSTP1-1 levels.6" 8 High serum GSTP1-1 
levels often normalized within 10-30 days after surgi­
cal removal of the malignancy.5,7
Because blood ceils and platelets contain large 
amounts of GSTP1-1, the sampling procedures for se­
rum or plasma are exceptionally critical. Howie et al.9 
described that platelet activation resulted in falsely 
elevated plasma GSTP1-1 levels. In a study of lung- 
carcinoma patients Howie et al,10 therefore used blood 
collection tubes (Trombotect tubes; Abbott Labora­
tories, North Chicago, IL) containing inhibitors of 
platelet activation (0.6 ml 2 .6% ethylenediaminetetra- 
acetic acid [EDTA], 0.025% 2-chloroadenosine, and 
7.0% procaine HCL), but their results were very similar 
to those obtained in serum from patients with gastro­
intestinal malignancies. s~a Hao et al.11 sampled blood 
in both standard EDTA as well as in Trombotect tubes 
and, surprisingly, reported much lower plasma 
GSTP1-1 levels in the standard EDTA tubes.
In the current study the authors describe the de­
velopment of a sandwich type enzyme-linked immu- 
noadsorbent assay (ELISA) for hum an GSTP1-1 based 
on a monoclonal-catching and a polyclonal-detecting 
antibody. The assay was used to measure plasma and 
serum GSTP1-1 levels in blood samples collected un­
der different conditions and in a variety of blood col­
lection tubes.
MATERIALS AND METHODS
Chemicals were of analytical grade and were obtained 
from Sigma (St. Louis, MO), unless otherwise stated.
Purification of GSTP1-1 and Preparation of the 
Antibodies
GSTP1-1 was purified from hum an placenta.12 Meth­
ods for production of the anti-GSTPl-1 monoclonal 
antibody (immunoglobulin [Ig]G2b antibodies with a 
k  light chain) were described previously.13,14 Rabbits 
were immunized by intracutaneous injection of 25 mg 
GSTP1-1 in complete Freund’s adjuvant and boostered 
twice by subcutaneous injection of 25 ¿¿g GSTP1-1 in 
incomplete Freund's adjuvant. IgG was purified using 
Sepharose CL4B-protein A columns (Pharmacia, Upp­
sala, Sweden).
ELISA Procedure
Assays were performed on polystyrene microtiter 
plates (Greiner, Alphen a/d Rijn, The Netherlands). All 
incubations were performed at room temperature in 
100 /iL/well, unless otherwise stated. In between incu­
bations, plates were washed 5 times with >200 ¡ j L I  
well phosphate-buffered saline (PBS) supplemented 
with 0.05% (volume/volume [v/v]) Tween 20 detergent 
(PBS-T). Plates were coated overnight at 4 °C with 10 
¿¿g/mL purified anti-GSTPl-1 monoclonal antibody in 
PBS and blocked with 200 ¿¿L/well PBS-T supple­
mented with 1 % (weight/volume [w/v]) bovine serum 
albumin (PBS-T-BSA) during 1 hour. Standard (0.4- 
100 fig/L GSTP1-1) diluted in PBS-T supplemented 
with 10 mmol/L EDTA and 10% (v/v) heat-treated nor­
mal human plasma (PBS-T-EDTA-NHP) and plasma 
samples diluted with an equal volume of PBS-T-EDTA- 
NHP then were added to the wells. Plates were incu­
bated overnight, washed, incubated with rabbit anti- 
GSTPl-1 antiserum diluted 1/1000 in PBS-T supple­
mented with 10% (v/v) heated normal human plasma 
for 3 hours, washed, and subsequently incubated for 
2 hours with peroxidase-labeled swine antirabbit (Da- 
kopatts, Glostrup, Denmark) diluted 1/2000 in PBS-T- 
BSA. After a final wash, plates were incubated with 
3.75 ¿¿mol/L o-phenylenediamine, 1 mmol/L H20 2 in 
24 mmol/L sodium citrate, 51 mmol/L Na2HP04, pH
5.0 for 15 minutes. The reaction was stopped by adding 
100 jiL  2 mol/L H2S04 and absorbance was read at 492 
nanometers (nm) with a background subtraction at 
620 nm, All standards and samples were measured in 
duplicate. A four-parameter weighted logistic regres­
sion model was used to calculate standard cuives and 
unknowns.
Test Samples
Within and between-assay coefficient of variation 
were calculated from 5 measurements of 10 plasma 
samples containing between 4.0-66.5 /xg/L GSTP1-1. 
Human donor plasma (endogenous GSTP1-1 concen­
tration of 24 /jg/L) was spiked with 0, 10, and 20 /¿g/L 
GSTP1-1 and served as control samples in every assay.
Analytic recoveries were determined in serum and 
in EDTA, heparin, and citrate plasma samples from 10 
healthy controls by spiking L6 , 3.2, 6.3, 12.5, 25.0, and
50.0 fig/L GSTP1-1. Plasma samples from patients with 
inflammatory bowel disease (n = 6) or colorectal tu­
mors (n = 6), healthy controls (n = 6), and cytosolic 
fractions from normal colon mucosa (n = 5) and colo­
rectal adenocarcinomas (n = 5), were used to evaluate 
whether serial dilutions of samples were parallel to the 
standard curve. GSTP1-1 levels in cytosolic fractions 
from 18 matched pairs of normal colonic mucosa and 
colorectal adenocarcinomas were measured by ELISA
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and compared with the results obtained by densitomet- 
ric analyses of immunoblots stained for GSTP1-1.15
Patients and Controls
EDTA plasma from 230 healthy blood donors (94 males 
and 136 females; median age, 35 years, range, 18-69 
years) visiting the Red Cross Blood Bank Nijmegen and 
from 107 patients with inflammatory bowel disease 
(41 males and 66 females; median age, 38 years, range, 
18-82 years) visiting the outpatient clinic of the De­
partment of Gastroenterology served as controls. 
EDTA plasma from 55 patients with gastrointestinal 
malignancies, (36 males and 19 females; median age, 
67 years, range, 44-95 years) was collected at the De­
partment of Surgery and the Department of Gastroen­
terology, St. Radboud University Hospital, Nijmegen, 
The Netherlands and at the Department of Gastroen­
terology and Hepatology, Hospital Gelderse Vallei, Be- 
nnekom, The Netherlands. Colorectal tumors were 
classified according to Dukes16 as modified by Astler 
and Coller.17 Tumors from the esophagus or stomach 
were staged according to the TNM classification of the 
International Union Against Cancer.10 Of the tumors 
from the eight patients with esophageal carcinoma 
two were Stage II, three were Stage III, and three were 
Stage IV. Two of the five patients with gastric carci­
noma had a Stage III tumor and three had a Stage IV 
tumor. Of the 33 colonic tumors 1 was Dukes Stage A, 
6 were Dukes Stage Bl, 14 were Dukes Stage B2, 7 
were Dukes Stage C2 , and 5 were Dukes Stage D. Of 
the nine rectal tumors one was Dukes Stage A, three 
were Dukes Stage Bl, three were Dukes Stage B2 and 
two were Dukes Stage D. From 17 patients who under­
went surgery for cure, (10 with a Dukes Stage B and 4 
with a Dukes Stage C colorectal tumor and 1 with 
a Stage II and 2 with a Stage IV esophageal tumor) 
postoperative plasma samples (median, 28 days after 
surgery; range, 15-120 days after surgeiy) were also 
available. Informed consent was obtained from all pa­
tients and blood donors.
The patients' plasma samples were collected in 
silicone-coated glass tubes containing K3EDTA. Imme­
diately after collection of the sample, blood was gently 
mixed with the EDTA solution. Tubes were centrifuged 
for 10 minutes at 3000 X g at room temperature within
2 hours. The upper two-thirds of the plasma was col­
lected and care was taken not to aspirate the platelets 
on top of the cell layer. Plasma samples were stored 
in portions at - 2 0  °C.
Miscellaneous
Blood collection tubes were obtained from Becton 
Dickinson (Grenoble, France) and from Sherwood
Medical (Ballymoney, Northern Ireland). Table 1 pro­
vides further specifications. The enzyme immunoas­
say for platelet factor 4 (PF4) was obtained from Stago 
Diagnostica (Asnieres-sur-Seine, France).
Amounts of GST protein in standard preparations 
were quantified by the Biorad protein assay (Biorad 
Laboratories, Munich, Germany) using a BSA standard 
line.
Human plasma was depleted of all immunoreac- 
tive GSTP1-1 by heating at 60 °C for 30 minutes.10
GST enzyme activity was assayed by the method 
of Habig et al.19 using l-chloro-2,4-dinitrobenzene as 
substrate. Specific activity of the GSTP1-1 standard 
preparation was 112 /xmol/minute * mg protein.
To evaluate the significance of differences be­
tween two groups, the Mann-Whitney U test or the 
Wilcoxon matched-pairs signed rank test was used. 
Differences between more than two groups were eval­
uated by Kruskal-Wallis analysis,
GSTP1-1 levels are expressed as median (range), 
unless otherwise stated.
This study was approved by the local Medical Ethi­
cal Review Committee.
RESULTS
Assay Performance
Coating concentration of the monoclonal antibody 
and dilutions of the rabbit antihuman GSTP1-1 antise­
rum and the swine antirabbit peroxidase were opti­
mized at 10 mg/L, 1/1000 and 1/2000, respectively. 
The detection limit of the resulting assay, correspond­
ing to 3 standard deviations above the mean signal of 
5 zero standards in duplicate, was 0.4 /¿g/L. GST-alpha 
and GST-mu in concentrations up to 10 mg/L dis­
played no detectable cross-reactivity.
Recoveries in spiked serum, citrate, heparin, or 
EDTA plasma were 80%, 86%, 82%, and 82%, respec­
tively. Twofold dilution of plasma samples from 
healthy controls and various patient populations or 
twofold dilutions of cytosolic fractions from normal 
colonic mucosa and colonic tumors were all parallel 
to the standard curve.
Within- and between-assay coefficients of varia­
tion ranged from 1.3-10.2% (mean, 5.8%) and from 
7.4-15.2% (mean, 10.9%), respectively. GSTP1-1 levels 
were also measured using both the ELISA and the semi- 
quantitative immunoblot assay in cytosolic fractions 
from 18 matched pairs of normal colonic mucosa and 
colorectal tumors. A good linear correlation (correla­
tion coefficient [r] = 0.85) was obtained between the 
two assays.
Influence of Sample Collection on GSTP1-1 Levels
GSTP1-1 levels in serum samples from ten healthy 
controls were higher than levels in the corresponding
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TABLE 1
Glutathione S-transferase Pl-1 Levels in Plasma and Serum, Collected in Different Tubes
GSTPl-l jig/L
Control no,
Plasma Serum
A B C D E F G H
1 5.8 4.8 4.6 2.8 4.2 20.4 28.2 17.4
2 5.8 7.0 5.4 4.2 5.0 11.0 16.8 8.6
3 5.2 4.8 5.4 5.0 4.6 13.6 29.8 14.4
4 5.6 6.0 6.4 5.4 6.2 11.6 23.8 14.2
5 5.8 5,2 5.4 5.2 5.0 17.6 21.8 15.6
6 8.2 6,0 7.2 5.6 5.6 15.4 32.4 13.6
7 1D.6 7.2 6.4 6.2 8.2 17.2 32.0 18.0
8 9.2 5.0 5.2 10.0 6.4 12.0 6.8 9.4
9 16.6 10.2 9.0 11.0 13.2 43.6 28.2 17.2
10 7.4 5.4 4.6 4.4 6.6 12.2 21.2 11.2
Median 6.6a 5.7 5.4 5.3 5.9 14.5a 26.0a 14.3a
Range 5.2-16.6 4.8-10.2 4,6-9.0 2.8-11,0 4.2-13.2 11.0-43.6 6.8-32.4 8.6-18.0
GSTPM: glutathione S-transferase P M . 
a P <  0.01 vs. Tube C.
Plasma and serum glutathione-S-transferase Pl-1 levels in ten  healthy controls as determ ined by enzyme-linked immunoadsorbent assay after collection of blood In eight different vacuum tubes. After venipuncture 
tubes were filled in random order. All blood samples were stored at room tem perature for 1 hour and centrifuged at 3000 x g for 10 minutes a t room temperature. Plasma or serum was subsequently stored at 
-2 0  °C until analysis.
Tube A: Sherwood Medical Monoject (Bailymoney, Northern Ireland) uncoated glass tube, 16 X 100 mm; additive: 0,10 mL 15% K3EDTA (Order no. 1000-311743).
Tube B: Becton Dickinson Vacutainer, (Grenoble, France) uncoated glass tube 13 X 75 mm; additive: 0.054 mL 15% K3EDTA (Order no. 367654).
Tube C: Becton Dickinson Vacutainer, silicone-coated glass tube, 16 x  75 mm; additive: 0.048 m l 15% K3EDTA (Order no, 606601).
Tube D: Sherwood Medical Monoject, silicone-coated glass tube, 12 x  75 mm; additive: 0.06 m l 7.5% K3EDTA (Order no. 1000-311000).
Tube E; Becton Dickinson Vacutainer Diatube H, glass tube w ith unknown coating, 12 X 75 mm; additives: citrate, theophylline, adenosine, and dipyrimidole (Order no. 367015),
Tube F: Sherwood Medical Monoject, silicone-coated glass tube, 16 x 100 mm, additive: none [Order no, 1000-301710).
Tube G: Sherwood Medical Corvac, silicone-coated glass tube, 16 x  100 mm; additives: powdered glass (cloth activator), inert plastic (energizer), and thixotropic (gel) (Order no. 8881-302015).
Tube H: Becton Dickinson Vacutainer, glass tube with unknown coating, 13 X 100 mm; additives; silica (cloth activator) and polyester (gel) (Order no. 367784).
EDTA plasma samples (Table 1). Moreover, serum 
GSTPl-l values varied with the blood collection tube 
used. GSTPl-l concentrations measured in EDTA 
plasma collected in different brands of blood collec­
tion tubes were more consistent (Table 1). When blood 
was sampled in plain EDTA tubes (Tube A) and centri­
fuged at 4 °C, high plasma GSTPl-l levels were found 
(28 /¿g/L; 11.8-55.2 /¿g/L) when compared with sam­
ples centrifuged at room temperature (6.6 ¿¿g/L; 5.2-
16.6 /¿g/L). In plasma sampled in EDTA tubes with 
a silicone coating (Tube C), no significant effect of 
refrigeration was noted (6.0 /¿g/L [4.4~8.2 /xg/L] vs. 5.4 
/¿g/L [4.6-9.0 /¿g/L]), when centrifuged at 4 °C and 
at room temperature, respectively. Plasma GSTPl-l 
levels in blood samples collected in plain, uncoated 
EDTA tubes (Tube A) increased from 6.6 /¿g/L (5 .2 -
16.6 /¿g/L) to 13.3 ¿¿g/L (10.8-33.6 //g/L) when tubes 
were centrifuged 1 and 6 hours after sampling, respec­
tively. In silicone-coated tubes (Tube C), no significant 
effect of delayed centrifugation was noted (5.4 /¿g/L 
[4.6-9.0 //g/L] vs. 5.3 /¿g/L [4.2-9.0 /¿g/L]) after storage 
for 1 and 6 hours at room temperature, respectively.
However, mild shaking of the silicone-coated EDTA 
tubes (Tube C) during 1 hour resulted in elevated 
GSTPM levels (14.6 ¿¿g/L [11.8-19.0 /¿g/L]). GSTPl-l 
values measured in plasma collected in EDTA tubes 
(Tubes A-D) were very similar to values obtained in 
samples collected in tubes containing citrate, theoph­
ylline, adenosine, and dipyrimidole (CTAD) (Tube E). 
However, CTAD plasma contained much lower levels 
of PF4 (30 IU/mL [17-64 IU/mL]) vs. 284 IU/mL [159- 
578 IU/mL]) for plasma collected in EDTA tubes (Tube 
C), indicating that even in silicone-coated EDTA tubes 
platelets had been activated.
GSTP1-1 in EDTA Plasma from Patients and Controls
Subsequently, all samples were collected in the same 
type of silicone-coated EDTA tubes (Tube C). Plasma 
GSTPl-l levels in 230 healthy controls displayed a lep- 
tokurtic positively skewed distribution that could be 
nearly normalized by logarithmic transformation. On 
the logarithmic scale the mean value was 7.8 /¿g/L and 
the reference range (mean ± 2 standard deviations) 
was 2.8-21.8 /¿g GSTPl-l per liter of EDTA plasma.
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TABLE 2
Plasma Glutathione S-transferase Pl-1 Concentrations in Healthy Controls Divided According to Gender and 
Age
jig/L G STPH , median (range), (no, of controls)
Age group (yrs) Males Females All
20-40 8.2 (3.8-33,6)* 5.5 (2.3-31.5)® 6.5 (2,3-33.6)g
(41) (81) (122)
40-60 9.1 (5.8-17.6)b 6.6 (4.0-71.6)f 7.8 (4,0-71.6)h
(32) (40) (72)
>60 12,0 (7.2-25.2)c 11.00 (5.1-24,2) 11.8 (5.1-25.2)
(20) (12) (32)
All ages 9.1 (3.8-33.6)d 6.2 (2,2-71,6) 7.2 (2*2-71.6)
(94) (136) (230)
GSTP1-1: glutathione S-lransferase Pl-1.
a Not significant vs. males 40-60 years; P = 0.0018 vs. males >60 years; P < 0.0001 vs. females 20-40 years. 
b P = 0.00187 vs. males >60 years; P = 0.0004 vs. females >40-60 years, 
c Not significant vs, females >60 years. 
dP< 0.0001 vs. aii females.
6 P = 0.0406 vs. females 40-60 years; P = 0.0002 vs. females >60 years. 
r P = 0.0320 vs. females >60 years,
BNot significant vs. 40-60 years; P < 0.0001 vs. >60 years. 
h p <  0.0001 vs, >60 years.
Ages of three females and one male were not recorded and therefore the numbers do not add up.
Males had significantly (P < O.OOOl) higher plasma 
GSTP1-1 levels than females and a significant (P <  
0,004) increase with age was noted both in males and 
females (Table 2). Patients with inflammatory bowel 
disease had slightly, but significantly (P < 0.02), lower 
plasma GSTP1-1 values (6.8 ¡1 g/L; 1.6-23,0 /¿g/L; n = 
107) than healthy controls (7.2 /¿g/L; 2.2-71.6 /¿g/L; n 
= 230).
When compared with the healthy controls, pa­
tients with gastrointestinal tumors had significantly (P 
< 0 .0001) elevated plasma GSTP1-1 levels (20.4 /¿g/L; 
8.2-216.8 /¿g/L) and in 20 of the 55 patients (36%) 
plasma GSTP1-1 levels were above the upper normal 
reference limit (Fig. 1). However, plasma GSTP1-1 lev­
els were not higher in patients with more advanced 
stages of colorectal carcinoma (Table 3) and no sig­
nificant effect of surgery was noted in 17 patients with 
a gastrointestinal tumor for whom plasma samples be­
fore and after resection of the tumor were available 
(Fig. 2).
DISCUSSION
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FIGURE 1. Plasma glutathione S-transferase P M  (GSTP1-1) levels in 
patients with various gastrointestinal malignancies. The dashed line de­
notes the upper normal reference limit.
>80% and serial dilutions of plasma and serum sam­
ples and dilutions of tissue homogenates were parallel 
to the standard curve. No significant cross-reactivity 
with GST-alpha or GST-mu (up to 10 mg/L) was ob­
served. In addition, results obtained in tissue homoge-
The sandwich ELISA used in the current study had a nates were comparable to levels obtained using the
detection limit and an intra- and interassay coefficient authors' semiquantitative immunoblot assay. All these
of variation comparable to previously published im- findings indicate that the measurements of GSTP1-1
munoassays for GSTP1-1.6’“9 Recoveries of spiked in plasma, serum, and tissue homogenates obtained
GSTP1-1 in several types of plasma and in serum were by the authors were accurate.
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TABLE 3
Plasma Glutathione S-Transferase Pl-1 Concentrations in Patients 
with Colorectal Carcinoma According to Stage of the Tumor
Tumor stage
jug/L GSTPl-l, median (range), 
(no. of patients)
Dukes A 21.1 (19.8-22.4)
(2)
Dukes B 21.3 (8.4-216.8)
(26)
Dukes C 18.6 (10.3-105.8)
(9)
Dukes D 14.8 (12.1-32.8)
(5)
GSTPl-l; glutathione S-transferase P M . 
Differences between groups were not significant,
a>
3
CLiHW
0
03
e
jfl
CL
FIGURE 2. Plasma glutathione S-transferase P1-1 (GSTP1-1) levels i
patients with carcinoma of the esophagus (open circles) or colorectum 
(closed circles). Samples were taken a few days before and > 14  days 
after surgery. The dashed line denotes the upper normal reference limit.
Collection of Samples
Hida et al.20 compared GSTPl-l levels in serum with
GSTPl-l levels of up to three times the upper normal 
reference limit for plasma. In the current study a simi­
lar difference between serum and plasma GSTPl-l lev­
els was detected. Moreover, the authors also detected 
major differences in serum GSTPl-l levels between 
serum samples collected in various types of tubes.
Howie et al.10 claimed that Trombotect tubes obvi­
ate spuriously high results of GSTPl-l in plasma by 
inhibiting platelet activation. To quantify platelet acti­
vation, they measured PF4, a protein secreted from 
the a  granules of stimulated blood platelets. Hao et 
al.11 also used Trombotect tubes but in their hands 
plasma collected in these tubes contained approxi­
mately fourfold to tenfold more GSTPl-l than plasma 
collected in standard EDTA tubes, whereas similar lev­
els of PF4 were measured in both sets of samples. 
Trombotect tubes were not for sale in The Netherlands 
and the authors used CTAD tubes, which were also 
developed to prevent platelet activation. In the au­
thors' hands plasma GSTPl-l levels in these tubes 
were similar as in EDTA tubes, although PF4 levels 
were almost tenfold higher in EDTA plasma. These 
data, together with the results from Hao et al.,11 sug­
gest that PF4 is an inadequate marker for GSTPl-l 
release from blood platelets.
Because EDTA tubes provided the lowest plasma 
GSTPl-l levels in healthy control subjects, the authors 
initially collected plasma samples in standard (un­
coated glass) EDTA tubes. Although most samples 
contained normal levels of GSTPl-l, occasional high 
levels were found, even in healthy controls. Subse­
quent experiments indicated that cooling the tubes to
4 °C before or during centrifugation increased GSTP1- 
1 levels in the resulting plasma almost threefold. A 
significant rise in plasma GSTPl-l levels was also 
noted when centrifugation was delayed for several 
hours. Howie et al.10 previously reported that GSTP1- 
1 levels in plasma samples collected in Thrombotect 
tubes increased within 2-3 hours after sampling. The 
authors of the current study concluded that plasma 
sampled in uncoated EDTA tubes was not suitable for 
plasma GSTPl-l measurements. In silicone-coated 
EDTA tubes no increase in plasma GSTPl-l levels due 
to cooling or delayed centrifugation of the tubes was 
noted. Fan et al.21 also used silicone-coated EDTA
those obtained in EDTA plasma from 50 patients. They tubes, but they also added procaine IiCL to inhibit
reported a significant linear correlation (r = 0.81) be- platelet activation.
tween serum and plasma GSTPl-l levels, but no fur- The results of the current study indicate that even
ther information was provided. Platelets contain major minor variations in the type of blood collection tubes 
amounts of GSTPl-l and the release of GSTPl-l by or in the procedures used to handle and centrifuge
activated platelets may lead to spuriously high GSTP1- 
1 levels in serum and plasm a .9 In a subsequent study
the blood and the subsequent aspiration of plasma 
samples may substantially affect the resulting GSTP1-
Howie et al.10 analyzed plasma and serum samples 1 levels. Therefore, only GSTPl-l levels measured in 
fiom eight controls and reported that serum contained samples collected in the same type of blood collection
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tubes and processed under identical conditions can 
be compared.
Reference Levels
Upper normal reference limits of 3.7 //g/L,8 15.4 /¿g/ 
L,7 34.0 /¿g/L,6 and 34.8 /¿g/L20 GSTPl-1 in serum, 30.4 
/¿g/L GSTP1-1 in heparin plasma,22 and 5.4 /¿g/L11 and 
13.99 /ig/L21 in EDTA plasma were reported in the liter­
ature, based on samples from 30-117 healthy controls. 
In none of these studies were differences between 
males and females or different age groups noted, and 
in all except one of the studies a normal distribution 
was assumed. Only Takahashi et al.6 reported that their 
normal reference values, based on 114 healthy con­
trols, had to be log-transformed to obtain a nearly 
normal distribution. These authors also demonstrated 
a slight increase in the serum GSTP1-1 levels after age 
70 years. The results of the current study in 230 healthy 
controls indicated that males had significantly higher 
GSTP1-1 levels in EDTA plasma than females. In both 
males and females a significant increase was noted 
with increasing age. In agreement with the results re­
ported by Takahashi et al.6 the current data had to be 
log-transformed to obtain a nearly normal distribu­
tion.
The authors also studied the plasma GSTP1-1 val­
ues in a large group of patients with inflammatory 
bowel disease, a disorder characterized by chronic, 
recurrent inflammation of the intestinal mucosa. 
GSTPl-1 levels in intestinal mucosa are relatively high 
and due to the process of inflammation some leakage 
of GSTP1-1 from the mucosa to the blood may occur, 
leading to increased plasma GSTP1-1 levels in these 
patients. However, slightly lower plasma levels were 
detected in patients with inflammatory bowel disease.
Patients with Gastrointestinal Tumors
In the current study, 36% (20 of 55) of the patients 
with esophageal, gastric, or colorectal carcinoma had 
elevated plasma GSTP1-1 values. In the study by Fan et 
al.21 73% (70 of 96) of the patients with gastrointestinal
tumors had elevated plasma GSTPl-1 levels. Corre-
i
sponding figures obtained in serum samples were 48% 
(40 of 83), 52% (39 of 75), and 64% (66 of 103) in the 
studies by Takahashi et al.,6 Tsuchida et al.,8 and Niitsu 
et al.,7 respectively.
The relatively low percentage of patients with ele­
vated GSTPl-1 levels in the current study may be re­
lated to the large percentage of patients with colorectal 
tumors (42 of 55; 76%). In the studies by Takahashi et 
al.,6 Tsuchida et al.,8 Niitsu et al.,7 and Fan et al.21 the 
majority of patients studied had gastric carcinoma. 
The lowest percentages of tumor patients with ele­
vated plasma GSTP1-1 levels were found by Takahashi
et al.6 and in the current study. This may be related 
to the logarithmic transformation of the normal refer­
ence values that was performed to calculate the upper 
normal reference limit. This transformation leads to a 
higher upper normal reference limit and consequently 
to a lower percentage of patients with elevated serum 
or plasma GSTPl-1 levels. Preliminary results in pa­
tients with oral carcinoma(8 of 56 patients; 14%; Oude 
Ophuis et al., unpublished data) or bladder carcinoma 
(10 of 40 patients; 25%; Berendsen et al., unpublished 
data) also indicated that only a small percentage had 
elevated plasma GSTPl-1 levels. Overall positivity of 
plasma/serum GSTPl-1 is comparable to other serum/ 
plasma markers for gastrointestinal malignancies such 
as carcinoembryonic antigen, CA 50, CA 19-9, CA 195, 
or others,23,24 which were also elevated in 30-60% of 
the patients.
Niitsu et al.7 and Fan et a l21 both reported that 
plasma or serum GSTPl-1 levels in patients with gas­
tric carcinoma were higher in patients with more ad­
vanced tumor stages. Similar results were reported for 
patients with nonsmall cell lung carcinoma and pa­
tients with oral carcinoma.22 In the group of patients 
with colorectal carcinoma studied by the authors, no 
significant relation between tumor stages and plasma 
GSTPl-1 levels was noticed.
Hirata et al.22 studied patients with oral carcinoma 
and reported an impressive decline in plasma GSTP1 - 
1 levels after surgical resection of the tumor; 16 of 25 
patients with a good prognosis had elevated GSTPl-1 
levels before surgery and all values had normalized 8 
weeks postoperatively. Similar investigations in pa­
tients with gastrointestinal tumors did not provide 
such striking results. Niitsu et al.7 reported a gradual 
decrease of serum GSTPl-1 levels in two patients with 
gastric carcinoma after resection. After 10 days serum 
GSTPl-1 levels had returned to values within the nor­
mal reference range. Fan et al.21 studied plasma 
GSTPl-1 levels in 18 patients with colorectal carci­
noma. In 8 of the 14 patients with an elevated preoper­
ative value (57%) they detected normal plasma GSTP1- 
1 levels within 14 days after surgery. Nineteen of the 
29 patients with esophageal carcinoma studied by 
Tsuchida et al.8 had an elevated preoperative serum 
GSTPl-1 level. In the serum of 9 of these 19 patients 
(47%) normal GSTPl-1 levels were measured after re­
section of the tumor. The authors studied 17 patients 
with gastrointestinal carcinomas before and after sur­
gical resection of the tumor. Eight patients had ele­
vated plasma GSTPl-1 levels before surgery and in 3 
of these patients (38%) these levels were within the 
normal range after removal of the tumor. However, of 
the 9 patients with normal preoperative plasma 
GSTPl-1 levels, 3 (33%) demonstrated elevated post­
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operative levels. Thus, the num ber of patients with 
elevated plasma GSTP1-1 remained unchanged after 
resection of the tumor, indicating that high plasma 
GSTPl-1 levels were not caused by leakage from the 
primary tumor.
The concentration of GSTP1-1 in serum and 
plasma samples depends mainly on the materials and 
methods used to collect the samples. In the current 
study siliconized EDTA blood collection tubes gave the 
lowest GSTPl-1 levels in healthy controls. Although > 
33% of the patients with gastrointestinal tumors had 
elevated plasma GSTPl-1 levels, follow-up experi­
ments after resection of the tum or indicated that the 
increased GSTPl-1 levels in plasm a may not be de­
rived from the tumor. Combined with the high proba­
bility of generating false-positive results due to inap­
propriate sampling, the findings of the current study 
argue against the use of GSTPl-1 as a routine plasma 
or serum tumor marker.
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